Skip to main content
. 2021 Mar 3;99(5):300–309. doi: 10.1159/000512967

b All treatment-related grade 3/4 toxicities occurring per cohort

Cohort Gemcitabine dose, mg/m2 Patients, n Hematological AEs, n
Gastrointestinal and hepatic AEs, n
Other toxicity AEs, n
DLTs, n SAEs, n
G3 G4 G3 G4 G3 G4
1 600 3 2 0 1 0 0 0 0 0
2 800 3 1 0 1 0 0 0 0 4
3 1,000 3 3 1 4 2 3 2 1 10
3 exp. 1,000 3 8 1 2 0 2 0 1 2

Total 12 2 16

AE, adverse event; DLT, dose limiting toxicity; SAE, serious adverse event.